Patients with hepatocellular carcinoma (HCC) have limited curative therapeutic options. In North America, liver transplantation is one of the most commonly used curative therapies.
Introduction
Hepatocellular carcinoma (HCC) is the third most common cause of cancer death in the world. It often occurs on a background of cirrhosis. Surgery offers the best hope for cure by either liver resection or transplantation. Liver resection is limited to patients with normal or mildly deranged liver function, with 50% 5-year survival and recurrence rate of 85% (1, 2). Orthotopic liver transplantation (OLT) of early HCC can result in 5-year survival rate of 70% and a recurrence rate of 15% (2-4). Unfortunately only 20% of patients are eligible for liver transplantation (3, 4) . Alternative therapeutic modalities include percutaneous ethanol injection, radiofrequency ablation (RFA), and trans-arterial chemoembolization (TACE).
HCC was traditionally considered a radio-resistant tumor. Prior to 3D conformal radiotherapy (3D-CRT), radiation oncologists were limited in the dose that could be delivered to the tumor in the liver. Conventional radiotherapy to large liver volumes is associated with high rates of toxicity, and significant radiation-induced liver disease (5). By contrast data from irradiation of limited liver volumes have been promising with an early local control rate of 85% (6) and 1 and 5-year overall survival rates ranging from 41% -92% and 6% -19% respectively (7-9).
Stereotactic radiotherapy is an evolution of radiotherapy technology which allows the delivery of high doses of radiation to small volumes with significant avoidance of surrounding normal liver and critical organs. as a bridge to transplantation. TACE treatment was initially suggested, but the angio-cath could not be passed due to the extensive false aneurysms. It was decided to refer the patient to radiation oncology for stereotactic body radiotherapy (SBRT).
In radiation oncology a total dose of 50 Gy in five fractions was planned. The planning target volume was enclosed within 96.1% isodose surface (Figure 2) . The treatment was delivered on alternating days using a standard linear acceleration with respiratory gating. Compared to pre-radiation, blood work improved with a serum bilirubin of 14.0 mmol/L and a serum albumin of 42 g/L. In addition there were no further events of hepatic encephalopathy or clinical ascites, based on this his Child-Pugh class became A.
Repeated imaging at 4 months post-treatment showed no change in the CT scan findings. However, the lesion was no longer seen in the CT scans that were done at 6, and 12 months post-treatment. The AFP dropped to 6 µg/L 9 months post-treatment.
The patient underwent liver transplantation 13 months post treatment. A jump graft to the aorta was used for the arterial anastomosis. Otherwise, the transplantation was uneventful.
On gross examination, the liver explant showed a scar-like lesion at the dome of the liver correlated to the treated area.
In this case-report, we present a patient with a HCC bridged to liver transplant by a course of sterotactic radiation which resulted in a complete histological resolution of the irradiated tumor.
Case Report
Our patient is a 60-year old male with a relevant past medical history of severe acute pancreatitis and type II diabetes. He was referred to the hepatology clinic with clinical features of cirrhosis, attributed to chronic alcohol intake.
At time of evaluation, the patient was alcohol-free for more than a year. His blood tests revealed an INR of 1.31 (normal range 0.8-1.2), albumin level of 31 g/L (normal range 38-50) and bilirubin level of 46.5 mmol/L (normal range 1.7-18.9). His Child-Pugh score was 10 (class C) with an expected 2-year survival of 35%. Due to the advanced stage of his cirrhosis, he was referred to the liver transplantation evaluation clinic.
During the workup, the patient required multiple admissions for encephalopathy, and his alpha-fetoprotein (AFP) level increased progressively to 11566 µg/L. A tri-phasic abdominal CT scan revealed a nodular liver compatible with cirrhosis and a new 2.2  2.3 cm hypodense lesion involving segments 7 and 8 (Figure 1) . Moreover, multiple aneurysms were also seen involving the splenic, gastroduodenal and superior mesenteric arteries. An MRI of the liver confirmed the CT scan findings in addition to other hyperplastic nodules of less than 2cm.
Current retrospective data confirm the relation between preoperative AFP levels and recurrence rate for HCC after liver transplantation (10). Local ablative therapy was suggested This ill-defined area of dense fibrosis had a discrete nodule within it. The discrete nodule consisted of an area of necrosis and fibrosis with no cancer cells.
Pathology
On gross examination, the native liver weighed 1100 g and had the diffusely nodular pattern characteristic of cirrhosis (Figure 3 ). There was a discrete scar-like lesion at the dome of the liver measuring 1 cm corresponding to the treated area (Figure 4a ). Microscopic examination revealed end stage liver cirrhosis compatible with alcoholic etiology. The discrete lesion consisted of areas of necrosis and fibrosis without malignant cells (Figure 4b ). In addition, distant from the site of radiotherapy, two well-differentiated HCCs were found measuring 0.6 and 0.5 cm.
Discussion
Mazzaferro et al., (3) reported a 4-year survival rate of 75% and a recurrence-free survival of 83% in patients who fit the Milan Criteria -either a single lesion  5cm or a maximum of three inter-hepatic lesions none measuring > 3 cm -after OLT. Similar results were reported in series from different parts of the world (2). However, other centers have published other prognostic features that can limit or expand the Milan criteria such as AFP slope, bi-lobar disease, lymph node involvement (11), poor-differentiation, microvascular invasion (12) in addition to size and stage (13).
A potential OLT candidate has up to a 30% dropout rate while on the transplant list, mostly for progression of disease (14, 15) . Local ablative techniques have been used as a bridge to transplantation, for local control in non-surgical candidates, and for palliation. Each modality has limitations relative to the patient's general health condition, location number and size used varied regimens of radiation including 14-26Gy / single fraction (22), 25Gy / 5 fractions, 30-37.5Gy / 3 fractions (21), and 24-54Gy / 6 fractions (20). From these and recent analogous series of SBRT for liver metastases (23, 24) it is not possible to show a strong correlation between dose schedule, response, and outcomes. For our patient 50Gy / 5 fractions was selected as the target volume was small and well removed from the bowel.
In a previous series, a significant drop in AFP was seen in 76% of patients with HCC treated with SBRT (20), with a median pre-treatment AFP of 3141 µg/L and a median postreatment AFP of 472 µg/L (20). Although pre-operative AFP level is a strong prognostic factor for predicting local recurrence after OLT (10), it is unclear if a treatment related decreased in the pre-operative level alters the natural history of the disease.
Although deterioration of Child-Pugh score has been described as an expected side effect of liver stereotactic radiotherapy (25), and Child-Pugh class C considered a contraindication to treatment, in our patient the focused treatment did not lead to deterioration in the liver function, and the patient did not have new episodes of encephalopathy. This is likely related to the small treatment volume and illustrates that each clinical situation should be evaluated individually.
Conclusion
Liver stereotactic body radiotherapy is a promising and safe treatment for patients with HCC. In selected patients, stereotactic body radiotherapy can be a bridge to transplantation and, on its own, has the potential to induce complete pathological response in non-surgical candidates.
